Sign in

CIK 0001515673

  • Large accelerated filer

Ultragenyx Pharmaceutical Inc.

Sign in to watch
Ticker
RARE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
272546083
Phone
+1 415-483-8800
Business address
60 LEVERONI COURT, NOVATO, CA, 94949
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$127,561
in 3 filings, $17K under 10b5-1 plans

Net −$127,561. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2020-08-17 Sharp Shalini CFO & Executive Vice President Exercise or conversion +500 $70.57 $35K 98,687
2020-08-17 Sharp Shalini CFO & Executive Vice President Sale −500 $88.38 $44K 98,187
2020-08-17 Sharp Shalini CFO & Executive Vice President Exercise or conversion +7,188 $67.55 $486K 105,375
2020-08-17 Sharp Shalini CFO & Executive Vice President Sale −7,188 $88.38 $635K 98,187
2020-08-17 Sharp Shalini CFO & Executive Vice President Exercise or conversion +3,669 $48.43 $178K 101,856
2020-08-17 Sharp Shalini CFO & Executive Vice President Sale −3,669 $88.38 $324K 98,187
2020-08-17 Sharp Shalini CFO & Executive Vice President Exercise or conversion · Stock Option (Right to Buy) −500 0
2020-08-17 Sharp Shalini CFO & Executive Vice President Exercise or conversion · Stock Option (Right to Buy) −7,188 15,812
2020-08-17 Sharp Shalini CFO & Executive Vice President Exercise or conversion · Stock Option (Right to Buy) −3,669 15,312
2020-08-10 SIEGALL CLAY B Director Sale −9,750 $85.01 $829K 2,550
2020-08-10 SIEGALL CLAY B Director Exercise or conversion +1,596 $40.37 $64K 4,146
2020-08-10 SIEGALL CLAY B Director Sale −1,596 $85.01 $136K 2,550
2020-08-10 SIEGALL CLAY B Director Exercise or conversion · Stock Option (Right to Buy) −1,596 0
2020-08-07 SIEGALL CLAY B Director Exercise or conversion +5,904 $40.37 $238K 18,204
2020-08-07 SIEGALL CLAY B Director Exercise or conversion +17,500 $21.00 $368K 35,704
2020-08-07 SIEGALL CLAY B Director Sale −23,404 $85.55 $2.0M 12,300
2020-08-07 SIEGALL CLAY B Director Exercise or conversion · Stock Option (Right to Buy) −5,904 1,596
2020-08-07 SIEGALL CLAY B Director Exercise or conversion · Stock Option (Right to Buy) −17,500 0
2020-07-13 KAKKIS EMIL D President & CEO Sale −40,000 $85.35 $3.4M 2,419,741
2020-07-08 Huizenga Theodore Alan SVP, Controller and PAO Sale −638 $91.00 $58K 16,582

Page 25 of 32 · 632 trades